Patient Phenotypes and SGLT-2 Inhibition in Type 2 Diabetes: Insights From the EMPA-REG OUTCOME Trial

A. Sharma,A. P. Ofstad,T. Ahmad,B. Zinman,I. Zwiener,D. Fitchett,C. Wanner,J. T. George,S. Hantel,N. Desai,R. J. Mentz

JACC: Heart Failure（2021）

引用 4|浏览10

暂无评分

摘要

Among participants with T2D, this study identified 3 phenotypes with varying CV risk. The treatment effect across phenotypes reaffirms the robustness of CV death or HHF reduction with empagliflozin. (BI 10773 [Empagliflozin] Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients [EMPA-REG OUTCOME]; NCT01131676).

查看译文

关键词

cardiovascular diseases,empagliflozin,latent class analysis,sodium-glucose transporter 2 inhibitors

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要